Cellectar Biosciences reveals Q3 2025 performance in high-stakes earnings call
Cellectar Biosciences, Inc. (CLRB) hosted its Q3 2025 earnings call on November 13, 2025, at 8:30 AM EST. The call was led by company executives and attended by analysts from Ladenburg Thalmann & Co. Inc., Oppenheimer & Co. Inc., and ROTH Capital Partners, LLC.
Cellectar Biosciences' call was headed by key company figures, including James Caruso (President, CEO & Director), Chad Kolean (VP, CFO & Secretary), and Jarrod Longcor (Chief Operating Officer). While analysts from Ladenburg Thalmann & Co. Inc. and ROTH Capital Partners, LLC were identified, the specific analyst from Oppenheimer & Co. Inc. was not mentioned in the available search results.
Cellectar Biosciences' Q3 2025 earnings call was a significant event, attended by top company executives and prominent financial analysts. Despite the lack of information about the specific Oppenheimer & Co. Inc. analyst, the call provided valuable insights into the company's performance and future prospects.
